E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Malignancies known to overexpress Gastrin-Releasing Peptide Receptors |
|
E.1.1.1 | Medical condition in easily understood language |
Breast, Prostate, Lung (non-small cell and small-cell) and Colo-rectal cancers |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10006187 |
E.1.2 | Term | Breast cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060862 |
E.1.2 | Term | Prostate cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061873 |
E.1.2 | Term | Non-small cell lung cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10041067 |
E.1.2 | Term | Small cell lung cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10061451 |
E.1.2 | Term | Colorectal cancer |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To characterize preliminary targeting properties of [68Ga]-NeoBOMB1 in patients with malignancies known to overexpress GRPR. |
|
E.2.2 | Secondary objectives of the trial |
•To assess safety and tolerability of a single diagnostic dose of [68Ga]-NeoBOMB1 administered as an intravenous bolus injection. •To assess the bio-distribution, pharmacokinetics, radiation dosimetry, and absorbed doses in critical organs for [68Ga]-NeoBOMB1 in a limited set of patients. •To establish the optimal threshold, expressed as Standardized Uptake Value (SUV), to discriminate Positron Emission Tomography (PET) imaging positive results from negative ones. •To estimate the [68Ga]-NeoBOMB1 PET imaging performance lesion-based and patient-based relative to a comparable standard imaging practice (eg PET, CT) according to the tumour type. •To estimate the [68Ga]-NeoBOMB1 PET diagnostic performance lesion-based and patient-based relative to the GRPR histopathology findings (e.g. IHC)
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Subjects must be at least 18 years of age •Subjects must have signed and dated an informed consent prior to any study-specific procedures. •Subjects with histologically-confirmed tumour, for whom a less than 6-month-old biopsy has been performed. •Dosimetry group: -Luminal breast cancer -Adenocarcinoma of the prostate •Non-dosimetry group: -Luminal breast cancer -Adenocarcinoma of the prostate -Small-cell lung cancer -Non-small cell lung cancer -Colorectal carcinoma •At least one malignant lesion detected via functional or morphological imaging (PET combined to appropriate tracer according to tumour type, CT, MRI) within 3 months prior to the administration of [68Ga]-NeoBOMB1. •The Eastern Cooperative Oncology (ECOG) performance status 0-2. •Subjects must agree to use highly effective methods of contraception (female partners of male participants should use highly effective methods of contraception) during the trial.
|
|
E.4 | Principal exclusion criteria |
•Renal insufficiency or an estimated Glomerular Filtration Rate (eGFR) <50 ml/min/1.73 m2. •Haematological toxicity grade > 2 (Toxicity Grading Scale in vaccine clinical trials) •Participation in any other investigational trial within 30 days of study entry. •Subjects with positive pregnancy test (Urine dipstick), and/or currently breast-feeding •Concurrent severe illness or clinically relevant trauma within 2 weeks before the administration of the investigational product that might preclude study completion or interfere with study results. •Concurrent bladder outflow obstruction or unmanageable urinary incontinence. •Known or expected hypersensitivity to 68Gallium, NeoBOMB1, or any excipient present in [68Ga]-NeoBOMB1. •Any condition that precludes raised arms position •Prior administration of a radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide. •History of somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
•Number and location of tumour lesions detected by [68Ga]-NeoBOMB1 overall and for each tumour type •Calculation of the ratio tumour/background SUV and calculation of percentage absorbed dose in tumour overall and for each tumour type.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Immediately after radiotracer injection, 4 scans with 6-7 bed positions will be acquired at approximately 15min, 1h±15min, 2h±15min and 4h±30min p.i. CT low dose attenuation scans will be acquired after every PET scan. PET data will be corrected for photon attenuation, dead-time, random events and scatter. A whole-body high dose CT will be acquired only if the conventional imaging of the patient is older than 1 month.
Patients of the non-dosimetry group will undergo 2 whole-body PET/CT scans at 90±30 min and at 150±30 min. Patients with prostate cancer will also undergo a 5-min static PET/CT scan on relevant regions for lymph node imaging purpose. A whole-body high dose CT will be acquired only if the conventional imaging of the patient is older than 4 weeks.
|
|
E.5.2 | Secondary end point(s) |
•Standard safety parameters (clinical monitoring, laboratory, ECG) •Tolerability and safety of the administration of a diagnostic dose of [68Ga]-NeoBOMB1 in patients with malignancies known to overexpress GRPR as determined by absence of: -increased number of SAEs compared to other peptide-based radiotracers; -clinically relevant changes of physiological parameters (blood pressure, heart rate, ECG findings) •Generation of decay corrected tissue TACs from [68Ga]-NeoBOMB1 PET/CT images in normal organs, tumour lesions. •Quantification of urinary excretion of [68Ga]-NeoBOMB1 •Calculation of half-life of [68Ga]-NeoBOMB1 in blood •Generation of non-decay-corrected time activity curves from [68Ga]-NeoBOMB1 PET/CT images in normal organs, tumour lesions •Calculation of residence times in organs and tumour lesions of [68Ga]-NeoBOMB1 •Calculation of absorbed doses and effective whole body dose of [68Ga]-NeoBOMB1 •Calculation of the SUV of each lesion •Number and location of tumour lesion detected by [68Ga]-NeoBOMB1 in comparison with comparable standard imaging modalities such as FDG-PET •Calculation of the [68Ga]-NeoBOMB1 PET overall, positive and negative agreement on a lesion-by-lesion basis as well as on a patient basis relative to the standard imaging overall and for each tumour type •Comparison of number of patients with tumour lesions detected and number of tumour lesions detected by [68Ga]-NeoBOMB1 with cytology and/or histopathology from archival and/or recent biopsy specimens •Calculation of the [68Ga]-NeoBOMB1 PET sensitivity and specificity on a lesion-by-lesion basis for all lesions with associated biopsy data, and on a patient basis relative to histopathology / cytology data
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immediately after radiotracer injection, 4 scans with 6-7 bed positions will be acquired at approximately 15min, 1h±15min, 2h±15min and 4h±30min p.i. CT low dose attenuation scans will be acquired after every PET scan. PET data will be corrected for photon attenuation, dead-time, random events and scatter. A whole-body high dose CT will be acquired only if the conventional imaging of the patient is older than 1 month.
Venous whole blood samples will be collected at pre-dose (0), 5, 10, 20, 30±5, 60±5 min, and at 2h±10 min and 3-4 h±10 min p.i. Urine samples from 0-2 h and from 2-4 h p.i. will also be collected.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will occur within maximum one month after the data base lock. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 9 |